Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The head space of 2C-I is described by many as one which is relatively normal in its thought processes even at moderate to high dosages. It is often said to lack insight when compared to that of 2C-E, 2C-B and LSD.
The visual geometry of 2C-I can be described as more similar in appearance to that of LSD or 2C-B than that of 2C-E, psilocin, or ayahuasca although it is much more bland and less detailed. They can be comprehensively described as unstructured in their organization, algorithmic in geometric style, intricate in complexity, large in size, fast and smooth in motion, colourful in scheme, glossy in colour, both soft and sharp in their edges as well as equally rounded and angular in their corners. They seem high in algorithmic visuals such as fractals and at higher dosages are significantly more likely to result in states of Level 7A visual geometry over Level 7B.
Like LSD, while 2C-I is capable of producing a full range of low and high level hallucinatory states, this is extremely rare and inconsistent at higher levels but common at lower levels.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
2C-I is not considered habit-forming and the desire to use it may actually decrease with repeated use, consistent with classical psychedelics. Some individuals may use it more frequently than intended, but psychological dependence is unlikely.
2C-I is not physically addicting and withdrawal effects following discontinuation have not been reported.
The lethal dose of 2C-I is unknown. This is due to its status as a research chemical with very limited history of human usage and no formal toxicological studies.
As with psychedelics generally, 2C-I may trigger latent psychological and mental problems in susceptible individuals. Those with a family history of schizophrenia or early onset mental illness should exercise extreme caution. Acute psychological effects such as disorientation, confusion, anxiety, and fear of death may occur during intoxication.
2C-I was first synthesized and investigated for human activity by Alexander Shulgin in the mid-to-late 1970s. The compound was initially described in scientific literature in 1977, with its properties and effects in humans documented the following year. Shulgin later provided a more comprehensive…
EU Council Decision 2003/847/JHA (December 2003) - Binding order compelling all member states to control 2C-I within three months
Prohibited substance under the Poisons Standard. The National Drugs and Poisons Schedule Committee formally added 2C-I to Schedule 9 (the most restrictive category) in 2005.
Added to the list of illegal psychotropic substances on November 8, 2004.
Controlled under the Controlled Drugs and Substances Act as of October 31, 2016.
Added to controlled substance lists in early 2011 alongside BZP, synthetic cannabinoids, and various cathinone derivatives.
Added to Schedule I in February 2011 alongside various synthetic cathinones and cannabinoids.
Added to the list of controlled substances in August 2004 as a synthetic analogue of mescaline.
Illegal to possess under Table A of Law 1729/87.
Added to the list of controlled substances in December 2007, making purchase, sale, and possession illegal.
Controlled under the Pharmaceutical Affairs Law, making possession and sale illegal.
Classified as a controlled substance under national drug legislation.
Classified as a controlled substance under national drug legislation.
Added to Schedule I by Sveriges riksdag on March 16, 2004, published in Medical Products Agency regulation LVFS 2004:3. Classified as a substance normally without medical use.
Classified as a drug. Possession, production, supply, and import are prohibited.
Controlled under the Synthetic Drug Abuse Prevention Act of 2012, effective July 9, 2012. Possession, distribution, and manufacture are federal offenses. Several states including Minnesota, Oklahoma, and Wisconsin had scheduled the substance prior to federal action.
Controlled under the Suchtmittelgesetz (Narcotics Act). Possession, production, and sale are prohibited.
Possession, production, and sale prohibited under Portaria SVS/MS nº 344. Controlled as of February 18, 2014.
Illegal to sell, buy, import, export, and manufacture as of September 2010.
Classified as a controlled substance since May 2002.
Scheduled under the government decree on substances, preparations, and plants considered to be narcotic drugs.
Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act) as of October 10, 1999. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without license are prohibited.
Controlled as a Schedule 1 substance, prohibiting possession and distribution.
Added to Tabella 1 (list of prohibited plants and substances) by Ministry of Health statement on January 11, 2005.
Classified as a Schedule I controlled substance.
Controlled under the catch-all analogues provision in Schedule 3 / Class C of national drug laws.
Legislation enacted in January 2005 to control 2C-I alongside 2C-T-2, 2C-T-7, and TMA-2.
Listed in Anhang D of the Betäubungsmittelverzeichnisverordnung (DetMV) since December 12, 1996. Possession is illegal.
Controlled under the Misuse of Drugs Act 1971 via the phenethylamine catch-all clause. Class A carries the most severe penalties for possession and supply.
15 sources cited
